LLLingjia Li

Lingjia Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lingjia Li has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Dajun Chai

    Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Key Laboratory of Metabolic Heart Disease in Fujian Province, Clinical Research Centre of Metabolic Cardiovascular Disease in Fujian Province

    2 shared publications
  • Feng Peng

    Fujian Hypertension Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, People’s Republic of China

    2 shared publications
  • Jinxiu Lin

    Department of Cardiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China

    2 shared publications
  • Chenxin Liao

    The First Affiliated Hospital, Fujian Medical University

    1 shared publication
  • Chenxin Liao

    The Higher Educational Key Laboratory for Cardiovascular Disease of Fujian Province, Clinical Research Center for Metabolic Heart Disease of Fujian Province, Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China

    1 shared publication
  • Jiaxing Ke

    The Higher Educational Key Laboratory for Cardiovascular Disease of Fujian Province, Clinical Research Center for Metabolic Heart Disease of Fujian Province, Cardiovascular Department, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China

    1 shared publication

Latest Publications

  • Open Access

    NEDD4L-Mediated Ubiquitination of GPX4 Exacerbates Doxorubicin-Induced Cardiotoxicity

    by Jiaxing Ke, Lingjia Li, Shuling Chen, Chenxin Liao, Feng Peng, Dajun Chai, Jinxiu Lin

    Doxorubicin (DOX) is an anthracycline chemotherapeutic agent that is clinically limited by doxorubicin-induced cardiotoxicity (DIC), with ferroptosis and apoptosis identified as key mechanisms. As an antioxidant enzyme, GPX4 undergoes ubiquitin-mediated degradation during myocardial ischemia–reperfusion injury; however, the role of its ubiquitination in DIC remains unclear. This study revealed that GPX4 undergoes ubiquitinated degradation during DIC, exacerbating ferroptosis and apoptosis in cardiomyocytes. NEDD4L was found to interact with GPX4, and its expression was upregulated in DOX-treated mouse myocardial tissues and cardiomyocytes. NEDD4L knockdown alleviated DIC, as well as ferroptosis and apoptosis in cardiomyocytes. Mechanistically, NEDD4L recognizes GPX4 through its WW domain and mediates K48-linked ubiquitination and degradation of GPX4 under DOX stimulation via its HECT domain. Knockdown of NEDD4L reduced DOX-induced GPX4 ubiquitination levels and subsequent degradation. Notably, while NEDD4L knockdown mitigated DOX-induced cell death, concurrent GPX4 knockdown attenuated this protective effect, indicating that GPX4 is a key downstream target of NEDD4L in regulating cardiomyocyte death. These findings identify NEDD4L as a potential therapeutic target for preventing and treating DIC.


  • Open Access

    Association of serum vitamin D levels with mortality in adults with H-type hypertension: Results from the NHANES database with traditional and machine learning approaches

    by Shuling Chen, Jiaxing Ke, Lingjia Li, Chenxin Liao, Feng Peng, Dajun Chai, Jinxiu Lin

    Objective: This study aimed to investigate the relationship between serum vitamin D (Vit D) levels and the risk of mortality among adults with H-type hypertension, a subtype of hypertension characterized by elevated homocysteine (Hcy) levels. Methods: This retrospective analysis utilized NHANES 2001 to 2006 to examine associations of Vit D and Hcy with mortality in hypertensive adults overall (n=5459), followed by targeted analyses in H-type hypertension (n=2276). The primary endpoints of the study were all-cause mortality and cardiovascular disease mortality, with follow-up through 2019. Weighted multivariable Cox models, mediation analyses, restricted cubic splines, and machine-learning validation were conducted. Results: In the overall hypertensive cohort, H-type hypertension had lower Vit D and higher mortality than non-H-type. Higher Vit D was inversely associated with mortality. Joint risk analysis showed greater risk reduction with Vit D>50 nmol/L and Hcy<10 μmol/L than with either factor alone. Hcy was a mediating factor in the relationship between Vit D and mortality. In H-type hypertension, Vit D showed a linear inverse association with mortality. Vit D was identified as an important variable through LASSO regression for feature selection. Five machine learning models were constructed, and three of them performed well in predicting mortality. Among Vit D-deficient individuals with H-type hypertension, engagement in moderate to vigorous activity was associated with a reduced risk of mortality. Conclusion: Higher serum Vit D levels linked to lower mortality risk in hypertension patients, including H-type hypertension, with significantly higher risk in severe deficiency (<25 nmol/L).